surmount-1 tirzepatide non-diabetic weight loss Trial surmount-1 trial tirzepatide obesity without

In the SURMOUNT-OSA trials, adults on tirzepatide lost an average of 45 lbs (18%) of their body weight (compared to 4 lbs (1.6%) adults on placebo), while adults on tirzepatide with PAP therapy lost an average of 50 lbs (20%) of their body weight (compared to 6lbs (2%) adults on placebo)

Once you know your concentration, you can calculate exactly how much liquid to draw for any dose

Tirzepatide (Zepbound) is now FDA-approved for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity

Incorporate regular movement: Consistent physical activity boosts metabolism and encourages better overall health

Packaged in 10ml bottles to preserve max potency

Telehealth companies, med spas, and compounded-medication suppliers are advertising these drugs aggressively, often without a real physical exam, real lab work, or real ongoing follow-up